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Background: The aim of this study was to evaluate acetylcholinesterase inhibitory activity of some commonly
used herbal medicine in Iran to introduce a new source for management of Alzheimer’s disease. A total of 18
aqueous-methanolic extract (1:1; v/v) from the following plants: Brassica alba, Brassica nigra, Camellia sinensis,
Cinchona officinalis, Citrus aurantifolia, Citrus x aurantium, Ferula assafoetida, Humulus lupulus, Juglans regia, Juniperus
sabina, Myristica fragrans, Pelargonium graveolens, Pistacia vera, Punica granatum, Rheum officinale, Rosa damascena,
Salix alba, and Zizyphus vulgaris were prepared and screened for their acetylcholinesterase inhibitory activity using
in vitro Ellman spectrophotometric method.
Results: According to the obtained results, the order of inhibitory activity (IC50 values, μg /ml) of extracts
from highest to the lowest was: C. sinensis (5.96), C. aurantifolia (19.57), Z. vulgaris (24.37), B. nigra (84.30) and
R. damascena (93.1).
Conclusions: The results indicated and confirmed the traditional use of these herbs for management of
central nervous system disorders. C. sinensis showed the highest activity in inhibition of acetylcholinesterase.
However, further investigations on identification of active components in the extracts are needed.
Keywords: Plant extracts, Acetylcholinesterase inhibitor, Alzheimer’s disease, Camellia sinensis,
Citrus aurantifoliaFinding
Alzheimer’s disease (AD) is a an age related neurodegen-
erative disorder with clinical characteristic and patho-
logical features associated with loss of neurons in certain
brain areas leading to impairment of memory, cognitive
dysfunction, behavioral disturbances, deficits in activities
of daily living, which eventually leads to death [1-3]. In
2010, approximately 35 million people worldwide were
suffering from AD and this number is believed to reach
65.7 million by 2030 [4].
Although the underlying pathophysiological mechanisms
are not clear, AD is firmly associated with impairment in
cholinergic pathway, which results in decreased level of
acetylcholine in certain areas of brain [1,2,5,6].* Correspondence: amanlou@tums.ac.ir
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stated.The management of AD focuses on slowing disease pro-
gression, symptomatic treatment, maintaining functional
status and improving quality of life, and decreasing
caregiver stress [5]. Acetylcholine, a neurotransmitter,
which is hydrolyzed by acetylcholinesterase (AChE) and
butyrylcholinesterase (BuChE) is considered to play an
important role in the pathology of AD [1,2,7].
The treatment of AD has progressed and shifted since
the late 1970s to a transmitter replacement strategy.
Elevation of acetylcholine levels in brain through the use
of AChE inhibitors has been accepted as the most effect-
ive treatment strategy against AD [3,8]. Therefore, AChE
and/or BuChE inhibitors have become the drug of
choice in management of AD [9]. Several AChE inhibi-
tors named as “cognitive enhancers “are being investi-
gated for the symptomatic treatment of Alzheimer’s
disease but few have been approved by the Food and
Drug Administration in the United States [2,8,10,11].
The few drugs that have received regulatory approvall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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antamine, all three working through increasing the
concentration of acetylcholine at the neurotransmitter
sites or acts by regulating activity at nicotinic receptors
[2,5].
However, studies investigating the use of medications
for AD have not been consistently supportive [12-17].
Various side effects of medications reported in clinical
trials include: nausea, vomiting, diarrhea, syncope and
bradycardia. Consequently, a need for development and
utilization of alternative anticholinesterase compounds
with fewer side effects leads to investigation on plants as
a possible source of treatment [18-26]. Plants have been
used since antiquity in the treatment of various diseases
including cognitive disorders, such as AD.Table 1 List of medicinal plants, traditional use and anticholi
Botanical name Plant family Parts tested Common nam
Brassica alba Brassicaceae Seed White mustard
Brassica nigra Brassicaceae Seed Mustard
Camellia sinensis Theaceae Leaf Tea
Cinchona officinalis Rubiaceae Bark Quina-quina
Citrus aurantifolia Rutaceae Fruit Key lime
Citrus x aurantium Rutaceae Flower Bitter orange
Ferula assafoetida Apiaceae Gum Asafoetida
Humulus lupulus Cannabaceae Flower Hop
Juglans regia Juglandaceae External shell Walnut
Juniperus sabina Cupressaceae Fruit Savin
Myristica fragrans Myristicaceae Seed Nutmeg
Pelargonium graveolens Geraniaceae Areal parts Rose geranium
Pistacia vera Anacardiaceae Hull Pistachio
Punica granatum Lythraceae Fruit Pomegranate
Rheum officinale Polygonaceae Root Rhubarb
Rosa damascena Rosaceae Flower Damask rose
Salix alba Salicaceae Bark White willow
Zizyphus vulgaris Rhamnaceae Fruit Jujube
* Traditional uses mentioned in this table are obtained from Avicenna’s cannon of m
of Iran.Considering the importance of plant-driven compounds
in drug discovery, the present study was undertaken to
evaluate the anticholinesterase activity of a number of se-
lected medicinal plants with various ethnobotanical uses,
aiming to discover new candidates for anticholinesterase
activity to be used in management of AD.
Material and methods
Plant materials
Eighteen medicinal plants, which are listed in Table 1
were chosen randomly from local herbal market in
September 2010, Tehran and identified by Dr. Faraz
Mojab. Voucher specimens were kept in the Herbarium
of Faculty of Pharmacy, Shahid Beheshti University of
Medical Sciences, Tehran, Iran.nesterase activity against electric eel acetylcholinesterase





Common cold, painful joints and
muscles, arthritis
135.0 ± 5.91
Relieve mental and physical fatigue,
antioxidant
5.96 + 0.73
Muscle relaxant, anti-malaria, palpitations,
anemia, diarrhea
187.6 ± 4.25
Alertness, anti-flatulent, uplifting and
cheering the spirit, common cold,
anti- inflammatory
19.57 ± 2.66












Antifertility, antioxidant, anti-inflammatory 379.9 ± 9.38
Diarrhea, mouth sores, and insomnia 1024. ±11.02





diarrhea, oral aphthous, hematopoiesis
408.2 ± 5.72
Astringent, antibacterial, laxative 341.7 ± 3.88
Cardiovascular stimulant, mild laxative,
anti-inflammatory, cough suppressant
93.1 ± 2.88
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Acetylthiocholine iodide (ATCI), 5,5’–dithio-bis-2-nitro-
benzoic acid (DTNB), bovine serum albumin (BSA) and
electric eel AChE (AChE; EC 3.1.17; lyophilized, 500 U/
vial solid, 65U/mg) were purchased from Sigma (St. Louis,
MO). Physostigmine was used as the standard drug. Buffers
and other chemical were of extra pure analytical grade. The
following buffers were used: Buffer A: 50 mM Tris–HCl,
pH 8, containing 0.1% BSA; Buffer B: 50 mM Tris- HCl,
pH 8 containing 0.1 M NaCl, 0.02 M MgCl2 × 6H2O.
Preparation of extracts
Each plant sample was individually powdered and 1 g of
each sample was extracted by maceration method under
shaking at room temperature with aqueous methanol
(20 mL; 1:1 v/v) for 24 h. After filtration, organic layer
was distilled under reduced pressure at 25°C and then
freeze-dried to dryness. The crude extracts were stored
at −20°C until analysis. Determination of fifty percent
inhibitory concentrations (IC50) at 100 μg/mL dissolved
in aqueous methanol was accurately defined.
Anticholinesterase inhibitory activity
Ellman’s method was employed for determination of
AChE inhibitory activity [26-28]. Acetylthiocholine was
used as a substrate and hydrolysis of acetylthiocholine was
determined by monitoring the formation of the yellow
5-thio-2-nitrobenzoate anion as a result of the reaction
with 5,5’–dithio-bis-2-nitrobenzoic acid with thiocholine,
catalyzed by enzymes at a wavelength of 412 nm.
Briefly, 25 μl of 15 mM ATCI, (43 mg/10 mL in Millipore
water), 125 μl of 3 mM DTNB, (11.9 mg/10 mL buffer B),
50 μl of buffer A and 20 μl of plant extract at concentra-
tion of 100 μ g/ml were added to 96 well plates and the
absorbance was measured at 412 nm every 13 s for five
times. After adding 25 μl of 0.22 U/ml enzyme, (0.34 mg
AChE dissolved in 100 mL buffer A), the absorbance was
read again every 13 seconds for five times. The absorbance
was measured using a Synergy H4 Hybrid Multi-Mode
Microplate Reader (BioTek Instruments Inc., United States).
Percentage of inhibition was calculated by comparing
rates of the sample with the blank (aqueous methanol),
control samples contained all components except the
tested extract. Physostigmine was used as positive control.
Then, the mean ofthree measurements for each concen-
tration was determined (n = 3). Inhibitory concentration
(IC50 value) was calculated according to Michaelis–
Menten model by using EZ-Fit. Enzyme Inhibition Kinetic
Analysis program (EZ-Fit: Enzyme Kinetics Software,
Perrella Scientific Inc., Amshert, USA).
Statistical method
The assays were conducted in triplicate (n = 3) and after
calculating the mean ± SD, the results were comparedusing Student’s t-test. A P value of less than 0.05 was
considered significant.
Results and discussion
Eighteen plant species belonging to 16 plant families
(Anacardiaceae, Apiaceae, Brassicaceae, Cannabaceae,
Cupressaceae, Geraniaceae, Juglandaceae, Lythraceae,
Myristicaceae, Polygonaceae, Rhamnaceae, Rosaceae,
Rubiaceae, Rutaceae, Salicaceae, and Theaceae) were
obtained from Tehran local herbal market and a total of
18 extracts were screened for AChE inhibitory activity
using Ellman’s spectrophotometric method in 96-well
microplate. Table 1 gives the names of the plants investi-
gated, their families, their traditional uses, and acetyl-
cholinesterase inhibitory concentration (IC50) respectively.
IC50 of physostigmine (positive control) was estimated
0.093 μM against AChE. At the test extracts concentration
(100 μg/ml), physostigmine showed complete inhibition of
enzyme activity.
Camellia sinensis
Results showed that AChE inhibitory concentration
(IC50) of leaves of C. sinensis (5.96 μg/ml) was less than
the inhibitory concentration (IC50) of the other tested
extracts (Table 1). An inhibitory activity has been
reported for green leaves of C. sinensis previously [29].
The occurrence of flavonoid saponins, polyphenols, and
catechins is well documented in different preparations of
C. sinensis. Quantitative concentrations of these com-
pounds in tea infusion might be different due to impact
of preparation method, cultivar, and agricultural diver-
gences, which might explain the observed difference in
AChE inhibitory activity between different types of
C. sinensis [30].
Citrus aurantifolia
In this study C. aurantifolia presented an IC50 inhibitory
effect of AChE in concentration of 19.57 (μ g/ml).
Report by Chaiyana and Okonogi [31] revealed inhib-
ition of cholinesterase by essential oil of leaf and fruit
peel of C. aurantifolia. Phytochemical investigations of
C. aurantifolia revealed the occurrence of limonene,
l-camphor, citronellol, o-cymene and 1,8-cineole as the
major constituents [31]; A group of compounds reported
to have AChE inhibitory activity [31]. Essential oils from
same family have been reported to posses promising
AChE inhibitory activity [32]. However, there is no
AChE inhibitory activity in blooms of C. aurantifolia.
Zizyphus vulgaris
The extract from Z. vulgaris fruit showed moderate
AChE inhibitory activity (IC50 = 24.37 μg/ml) in this
study, which is similar to the results of previous studies
[33,34]. The AChE inhibitory activity of Z. vulgaris can
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flavonoids in the extract [33].
Rosa damascena
We found AChE inhibitor activity from R. damascena
floret extract (IC50 = 93.10 μg/ml) that is not in sup-
ported in previous investigations [25]. The R. damascena
floret jam is used traditionally as a sweetener to tea to
increase memory and wellness.
Brassica nigra
There is limited data on seeds of B. nigra. This study
shows that seeds of B. nigra present AChE inhibitory
activity with an IC50 of 135.0 (IC50 = 93.10 μg/ml). This
finding suggests a moderate inhibitory activity for B. nigra
seeds. Though further investigation in active components
of the extract is needed.
The promising finding of the study shows that most of
the plant-extracts screened in this study had some de-
grees of inhibitory activity against AChE (Table 1), but
five species showed the most active inhibitory property
(C. sinensis, C. aurantifolia, Z. vulgaris, B. nigra, and R.
damascena) and had lowest inhibitory concentration
below 100 μg/ml ranging between 5.96 to 93.10 against
electric eel AChE. The extract of the herbs alone or in
combination of other herbal productions such as essen-
tial oil could be considered in herbal remedies of AD
management. Since the most strong synthetic or natural
product driven AChE inhibitors are known to contain
nitrogen, the promising activity of reported medicinal
plants could be due to their high alkaloidal contents
[35-40]. Alkaloids are the major compounds isolated
from plants and show inhibitory activity for AChE
[35-40] but only one out of each five most potent species
contains alkaloids.
The search performed using Chemical Abstracts, Biological
Abstracts and Scopus database shows that AChE in-
hibitory activity is not only limited to alkaloids but also
other compounds such as flavonoid, coumarins and es-
sential oils are reported to have AChE inhibitory activ-
ity [35-41]. The finding of this study shows that the
four most active herbal extracts contained not only
nitorgenic compound such as alkaloid but also these
extracts also contain rich components of saponin,
flavonoid, and essential oils [29-34]. The new area of
interest in research involves both AChE inhibitors and
BuChE inhibitors after recognition of BuChE activity in
hippocampus of patients with AD [33,42,43]. Recent
studies have work on dual inhibitors of AChE and
BuChE [42,43]. In these studies synthesized chemical
compounds have shown promising inhibitory effect on
both AChE and BuChE [42-44]. However, the present
study was limited to the screening of AChE inhibitory
properties of selected plants. Thus, further studiesshould focus on BuChE inhibitory activity of herbal
products of the plants used in this study and other
potent plants.
Conclusions
A primary screening process was run to investigate
AChE inhibitory properties of medicinal plants of Iran.
The primary findings of this study suggest that all herbs
used in this study exhibited some degree of AChE
inhibitory properties. Among the selected plants of this
report C. sinensis had the most active components with
inhibitory properties on AChE. Further researches should
investigate more on the chemical composition and mech-
anism of actions of these herbal extract including in vitro
and in vivo studies.
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